logo
Jakarta to trial car-free night at end of June

Jakarta to trial car-free night at end of June

The Star2 days ago

People exercising in the rain on Feb 9, 2025, during a car-free day at the Hotel Indonesia traffic circle in Central Jakarta. - Antara
JAKARTA: The Jakarta administration will trial a Car Free Night (CFN) in conjunction with the city's 498th anniversary. The trial will be held after the celebrations end at the end of June.
The trial will take place in the Jl. Sudirman-Jl. Thamrin thoroughfare, where the current Car Free Day (CFD) events take places.
Jakarta Deputy Governor Rano Karno said that the planned CFN is the city's response to the public's preference to get physical activity in the evening.
It is also expected that the CFN will reduce carbon emissions and create an environmentally friendly public space.
'We will try out the Car Free Night from 10pm, as there are also many people exercising in the evening,' Rano said when attending a CFD activity on Sunday, as quoted by the Antara news agency.
'The location is the same [on Jl. Sudirman-Jl. Thamrin].'
The CFN is scheduled to take place on Saturday evening while the CFD is currently held every Sunday morning. This is meant to take advantage of the weekend when many Jakartans go out to play sports, relax or enjoy the city.
'If the CFD is focused on health, now we add with CFN with a focus on happiness,' Rano said.
As part of the launch of the CFN, the Jakarta administration will also hold Betawi arts and cultural performances at three locations: Bung Karno Sports Complex, Dukuh Atas and the Hotel Indonesia traffic circle.
'We start the activity here [in Dukuh Atas]. Next month we will add more locations in Bung Karno Sports Complex and around the Hotel Indonesia traffic circle,' Rano said.
The arts shows will start on June 29 with a target of 5,000 participants performing various Betawi arts and cultural performances, such as pencak silat, traditional dances, songs and food.
'Arts and cultural performances here will not only improve health but also make citizens happy,' Rano said.
Other than the CFN trial, the Jakarta administration is also looking to expand the CFD to all five townships in Jakarta as part of its commitment to making Jakarta a green, healthy and happy global city.
Rano said that the CFD had been proven to reduce carbon emissions. 'Carbon emissions are reduced but it was only for a day,' he said. 'Ideally, we can make it two days, Saturdays and Sundays. But Saturdays are for economic [activities].'
'There is a plan to hold it in five locations, we are still looking for them.' One of the areas targeted by the city administration is North Jakarta for its high carbon emissions.
'Especially North Jakarta because there are factories [there] so the emissions and pollutions there are very high,' Rano said.
'This means that we have to find a place to reduce carbon emissions.' Jakarta was the pioneer for the CFD, with initial efforts conducted to commemorate the World CFD on Sept. 22, 2002, by closing down Jl. MH Thamrin from 6am, to 6pm. The initiative was created by a coalition of environmental NGOs.
Initially, the CFD was held on the last week of the month in Jakarta from 6am to 2pm. But because of complaints from the public, it was shortened by two hours starting on April 26, 2009.
In 2011, the CFD was held twice a month and starting on May 13, 2012, it was held every week from 6am to 11am.
Other cities have instituted their own CFD arrangements, ranging in frequency from once a month, such as in Tangerang and Bandung, to once a week in Bekasi and Depok. - The Jakarta Post/ANN

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview
2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview

USA Today

time25 minutes ago

  • USA Today

2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview

2025 Libema Open: Branstine [231st] vs. Ruse [80th] Prediction, Odds and Match Preview Carson Branstine (No. 231 ranking) will take on Elena-Gabriela Ruse (No. 80) in the Round of 16 of the Libema Open on Thursday, June 12. Ruse is the favorite against Branstine for this match, with -275 odds against the the underdog's +270. Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 6:35 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Carson Branstine vs. Elena-Gabriela Ruse matchup info Tournament: Libema Open Libema Open Round: Round of 16 Round of 16 Date: Thursday, June 12 Thursday, June 12 Court Surface: Grass Watch the Tennis Channel and more sports on Fubo! Branstine vs. Ruse Prediction Based on the implied probility from the moneyline, Branstine has a 73.3% to win. Branstine vs. Ruse Betting Odds Branstine vs. Ruse matchup performance & stats

Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says
Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says

CNBC

time25 minutes ago

  • CNBC

Elon Musk's favorability among Republicans dropped 16 points since March, Quinnipiac says

Elon Musk's official role in the Trump administration recently came to an end. Many Republicans won't be sad to see less of him, according to the results of Quinnipiac University's latest public opinion survey. While a majority of Republicans still hold a favorable view of Musk, the number fell to 62% in the poll out Wednesday, down from 78% in March, Quinnipiac said. Overall, the Quinnipiac poll found that 30% of self-identified voters surveyed in the U.S. hold a favorable opinion of Musk, according to polling from June 5 to June 9. Republican and Democratic voters remain deeply divided in their views of the world's richest man, who contributed nearly $300 million to propel President Donald Trump back to the White House. Only 3% of Democrats surveyed said they held a favorable of view of the Tesla CEO, who was once seen as an environmental leader appealing to liberal values. Musk didn't respond to a request for comment. Musk and Trump had a very public falling out last week that started with Musk's disapproval of the president's spending bill and escalated into an all-out war of words that played out on social media. Musk said on Wednesday that he regretted some of the posts he made about Trump last week, adding that "they went too far." Even with a slide in his favorability, Musk is still popular among Republicans after his time running the Department of Government Efficiency (DOGE), an effort to dramatically slash the size of the federal government. Among the Republican respondents to the early June poll, 80% rated Musk and DOGE's work as either excellent or good, while 13% said it was either not so good or poor. In the March poll, 82% of Republicans surveyed said they thought Musk and DOGE were helping the country. Read the full survey results here.

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Yahoo

time25 minutes ago

  • Yahoo

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store